Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles

argenx SE

07/05/2026 06:08

Overview

Netherlands immunology firm's Q1 product net sales rose 63% yr/yr to $1.3 bln

Q1 net profit more than doubled yr/yr to $366 mln, diluted EPS rose to $5.52

Growth driven by continued VYVGART adoption and pipeline progress

Outlook

Company expects PDUFA decision for seronegative gMG on May 10, 2026

Topline results from ALKIVIA study (myositis) expected in third quarter of 2026

VYVGART SC autoinjector expected to launch in 2027 for all approved indications

Result Drivers

VYVGART ADOPTION - Company said strong Q1 growth was driven by continued global adoption of VYVGART

PIPELINE INVESTMENT - Higher R&D expenses mainly related to advancing efgartigimod, empasiprubart, and early-stage programs

COMMERCIALIZATION SPEND - Increased selling, general and administrative expenses linked to global commercialization of VYVGART franchise

Company press release: ID:nGNEbTYfS5

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
$5.52
Q1 Net Income
$366 mln
Q1 Basic EPS
$5.90
Q1 Operating Expenses
$919 mln
Q1 Total Operating Income
$1.31 bln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for argenx SE is €876.00, about 27.3% above its May 6 closing price of €688.40

The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 28 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)